Emerging Role of Molecular Testing in the Management of Non-metastatic Non-small Cell Lung Cancer
Advances in targeted therapies and immune checkpoint inhibitors have significantly enhanced survival rates for patients diagnosed with metastatic non-small cell lung cancer (NSCLC). In non-metastatic NSCLC, adding immune checkpoint inhibitors postchemoradiotherapy has led to improved outcomes in sta...
Saved in:
| Main Author: | Hidenori Kage |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2025-07-01
|
| Series: | Tuberculosis and Respiratory Diseases |
| Subjects: | |
| Online Access: | http://e-trd.org/upload/pdf/trd-2024-0159.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Curative immunotherapy-based strategies for non-metastatic non-small cell lung cancer
by: Justin J. Kuhlman, et al.
Published: (2024-12-01) -
Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy
by: Ulas Kumbasar, et al.
Published: (2025-06-01) -
Adjuvant therapy in resected non-small cell lung cancer: current status and perspectives
by: Robert Pirker
Published: (2025-03-01) -
Perioperative Treatment in EGFR‐Mutant Early‐Stage Non‐Small Cell Lung Cancer: Current Evidence and Future Perspectives
by: Xiaobei Guo, et al.
Published: (2025-02-01) -
Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer
by: Weizhen SUN, et al.
Published: (2024-11-01)